Terto SV, Araújo ST, Negreiros FDDS, Brasil BMBL, da Cunha GH, Rodrigues AB, de Carvalho MMD, Gadelha DD, Carioca AAF, Oliveira Fernandes V, Montenegro Júnior RM. Risk Factors Associated With New-Onset Diabetes After Liver Transplant: A Case Control Study.
Transplant Proc 2019;
51:1956-1961. [PMID:
31303408 DOI:
10.1016/j.transproceed.2019.04.030]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 04/10/2019] [Accepted: 04/22/2019] [Indexed: 01/23/2023]
Abstract
BACKGROUND
New-onset diabetes after transplant is a severe complication that can present in liver transplant recipients, negatively impacting quality of life and graft survival. It also contributes to increased risk of infection, cardiovascular disease, and rejection, which are the main causes of death among liver transplant recipients. The aim of the present study was to assess the risk factors associated with new-onset diabetes after transplant.
METHOD
This was a case control study based on the data from 146 liver transplant patients at a reference hospital. The data from the charts were collected using a 2-part form: Part I (sociodemographic variables) and Part II (clinical variables).
RESULTS
Multiple analysis showed that pre-existing systemic arterial hypertension (odds ratio [OR], 2.65; 95% CI, 1.12-6.28) and the use of sodium mycophenolate associated with tacrolimus (OR, 2.68; 95% CI, 1.02-7.06) increased the risk of new-onset diabetes after transplant. On comparing the anthropometric variables, lipid panel, and blood glucose levels of liver transplant patients with and without diabetes, higher glycemic levels were found in the group with diabetes (P < .001).
CONCLUSION
Pre-existing systemic arterial hypertension and the associated use of sodium mycophenolate and tacrolimus increased the risk of new-onset diabetes after transplant.
Collapse